ABG Sundal Collier acted as Sole Global Coordinator and Sole Bookrunner in the SEK 120m directed share issue in Guard Therapeutics

The board of directors of Guard Therapeutics International AB (publ) has decided to carry out a directed share issue of 160,000,000 shares, at a subscription price of SEK 0.75 per share, corresponding to issue proceeds of SEK 120 million. The subscription price was determined through an accelerated bookbuilding procedure conducted by ABG Sundal Collier AB as Sole Global Coordinator and Sole Bookrunner.
The investors in the Directed Share Issue comprised a number of institutional, professional and specialist investors, including Stiftelsen Industrifonden, Swedbank Robour Fonder, Strand Kapitalförvaltning and Arctic Asset Management.
The net proceeds from the Directed Share Issue are intended to be used to secure the completion of the Company’s phase 2 study (AKITA) and to finance selected preparatory phase 3 activities including CMC development